

Joseph P Nkolola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2719883/publications.pdf>

Version: 2024-02-01

46
papers

7,174
citations

159525

30
h-index

206029

48
g-index

49
all docs

49
docs citations

49
times ranked

12213
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
2	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
3	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
4	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
5	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
6	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015, 349, 320-324.	6.0	303
7	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
8	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
9	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	6.3	269
10	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
11	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246
12	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364.	13.7	246
13	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
14	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	5.1	124
15	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	106
16	Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs. <i>Journal of Virology</i> , 2010, 84, 3270-3279.	1.5	89
17	Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. <i>Journal of Virology</i> , 2021, 95, .	1.5	87
18	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. <i>Journal of Virology</i> , 2021, 95, .	1.5	80

#	ARTICLE	IF	CITATIONS
19	SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. <i>Cell Host and Microbe</i> , 2016, 19, 323-335.	5.1	78
20	Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies. <i>PLoS ONE</i> , 2014, 9, e97229.	1.1	59
21	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. <i>Nature Medicine</i> , 2018, 24, 721-723.	15.2	46
22	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1030-1043.	11.6	46
23	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
24	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	15.2	43
25	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. <i>Journal of Virology</i> , 2015, 89, 2507-2519.	1.5	42
26	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
27	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
28	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	38
29	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1061-1070.	4.6	36
30	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	1.9	35
31	First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. <i>PLoS ONE</i> , 2018, 13, e0205139.	1.1	32
32	Lack of therapeutic efficacy of an antibody to $\hat{I}^{\pm} ₄ \hat{I}^2 ₇$ in SIVmac251-infected rhesus macaques. <i>Science</i> , 2019, 365, 1029-1033.	6.0	31
33	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. <i>Journal of Virology</i> , 2014, 88, 9538-9552.	1.5	30
34	Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. <i>Vaccine</i> , 2014, 32, 2109-2116.	1.7	27
35	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , 2021, 12, 1474.	5.8	26
36	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25

#	ARTICLE	IF	CITATIONS
37	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq1 2.0.7843149rgBT /Ov	2.1	15
38	HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. PLoS Pathogens, 2022, 18, e1010467.	13.7	14
39	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. Nature, 2022, 601, 612-616.	5.8	11
40	Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nature Communications, 2017, 8, 15740.	2.2	11
41	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med, 2022, 3, 188-203.e4.	1.5	10
42	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. Journal of Virology, 2018, 92, .	1.2	7
43	Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. American Journal of Reproductive Immunology, 2020, 84, e13288.	2.2	4
44	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. Frontiers in Immunology, 2021, 12, 709994.	2.9	4
45	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	5.8	3
46	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. Science Translational Medicine, 2022, 14, .		